Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -3.33 is 14% below its 5-year average of -2.91, around the middle of its 5-year range (-7.74–0.35).
23.33% below its 12-month average of -2.70.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.84.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T13:25:28.043Z. Historical observations retain their original dates. Historical series through 2024-03-14.
EARNINGS PER SHARE (EPS)
-3.33
EARNINGS PER SHARE (EPS) AVG TTM
-2.70
EARNINGS PER SHARE (EPS) AVG 3Y
-1.54
EARNINGS PER SHARE (EPS) AVG 5Y
-2.91
EARNINGS PER SHARE (EPS) AVG 10Y
-3.44
EARNINGS PER SHARE (EPS) AVG 15Y
-3.47
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
-23.33%
CURRENT VS 3Y AVG
-115.88%
CURRENT VS 5Y AVG
-14.43%
CURRENT VS 10Y AVG
+3.15%
CURRENT VS 15Y AVG
+3.94%
CURRENT VS 20Y AVG
N/A
Arcturus Therapeutics Holdings Inc.
Market Cap
$416.68M
Earnings Per Share (EPS)
-3.33
TTM Avg
-2.70
3Y Avg
-1.54
5Y Avg
-2.91
Market Cap
$415.93M
Earnings Per Share (EPS)
-1.36
TTM Avg
-1.81
3Y Avg
-2.62
5Y Avg
-2.62
Market Cap
$410.54M
Earnings Per Share (EPS)
-2.08
TTM Avg
-1.97
3Y Avg
-1.74
5Y Avg
-0.94
Market Cap
$408.21M
Earnings Per Share (EPS)
-4.63
TTM Avg
-6.16
3Y Avg
-6.16
5Y Avg
-6.16
Market Cap
$406.47M
Earnings Per Share (EPS)
-1.71
TTM Avg
-1.36
3Y Avg
-1.12
5Y Avg
-1.12
Market Cap
$428.16M
Earnings Per Share (EPS)
-0.75
TTM Avg
-2.34
3Y Avg
-2.48
5Y Avg
-2.46
Market Cap
$447.43M
Earnings Per Share (EPS)
-2.45
TTM Avg
-1.70
3Y Avg
-1.35
5Y Avg
-1.20
Market Cap
$384.23M
Earnings Per Share (EPS)
-2.94
TTM Avg
-3.49
3Y Avg
-2.70
5Y Avg
-2.28
Market Cap
$450.64M
Earnings Per Share (EPS)
0.55
TTM Avg
-3.62
3Y Avg
-10.86
5Y Avg
-15.74
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Arcturus Therapeutics Holdings Inc. (ARCT) | $416.68M | -3.33 | -2.70 | -1.54 | -2.91 |
| Carlsmed, Inc. (CARL)vs › | $415.93M | -1.36 | -1.81 | -2.62 | -2.62 |
| Atea Pharmaceuticals, Inc. (AVIR)vs › | $410.54M | -2.08 | -1.97 | -1.74 | -0.94 |
| Eikon Therapeutics, Inc. Common Stock (EIKN)vs › | $408.21M | -4.63 | -6.16 | -6.16 | -6.16 |
| Shoulder Innovations, Inc. (SI)vs › | $406.47M | -1.71 | -1.36 | -1.12 | -1.12 |
| Editas Medicine, Inc. (EDIT)vs › | $428.16M | -0.75 | -2.34 | -2.48 | -2.46 |
| Capricor Therapeutics, Inc. (CAPR)vs › | $447.43M | -2.45 | -1.70 | -1.35 | -1.20 |
| Kyverna Therapeutics, Inc. (KYTX)vs › | $384.23M | -2.94 | -3.49 | -2.70 | -2.28 |
| Assembly Biosciences, Inc. (ASMB)vs › | $450.64M | 0.55 | -3.62 | -10.86 | -15.74 |
| DiaMedica Therapeutics Inc. (DMAC)vs › | $453.70M | -0.72 | -0.65 | -0.60 | -0.64 |
Trailing EPS (TTM)
$-3.33
Forward EPS (Est.)
$-3.40
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -2.40 |
| 2024-12-31 | -3.00 |
| 2023-12-31 | -1.12 |
| 2022-12-31 | 0.35 |
| 2021-12-31 | -7.74 |
| 2020-12-31 | -3.55 |
| 2019-12-31 | -2.13 |
| 2018-12-31 | -2.16 |
| 2017-12-31 | -3.53 |
| 2016-12-31 | -6.25 |
| 2015-12-31 | -6.29 |
| 2014-12-31 | -16.81 |
| 2013-12-31 | -7.25 |
| 2012-12-31 | -0.99 |
| 2011-12-31 | -2.47 |
